Humanising Antibodies by CDR Grafting

  • Siobhan O’Brien
  • Tarran Jones
Part of the Springer Lab Manuals book series (SLM)


Following the original discovery of the process for making mouse monoclonal antibodies by Kohler and Milstein in 1975 a tremendous amount of effort has been expended to isolate mouse antibodies against specific antigenic targets, creating a huge reservoir of potential therapeutic agents. Unfortunately, the numerous limitations associated with the long term use of mouse monoclonal therapeutic antibodies have been so severe that until recently, very few monoclonal antibodies had been licensed for human use in the intervening time. The major stumbling blocks to their use as therapeutic agents include:
  • • Short serum half life.

  • • Poor utilisation of human effector functions via the mouse constant regions.

  • • Rapid onset of a human anti-globulin response to mouse specific residues — also known as the HAMA (Human Anti-Mouse Antibody) response.


Polymerase Chain Reaction Reaction Chimeric Antibody Potential Glycosylation Site Polymerase Chain Reaction Reaction Mixture Variable Region Gene 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Chomczynski P, and Sacchi N (1987) Anal Biochem 162: 156PubMedCrossRefGoogle Scholar
  2. Chothia C, and Lesk AM (1987) J Mol Bio 196: 90CrossRefGoogle Scholar
  3. Chothia C, Lesk AM, Gherardi E, Tomlinson IM, Walter G, Marks JD, Llewelyn MB, and Winter G (1992) J Mol Bio 227: 799CrossRefGoogle Scholar
  4. Chothia C, Lesk AM, Tramontano A, Levitt M, Smith-Gill SJ, Air G, Sheriff S, Padlad EA, Davies A, Tulip WR, Colman PM, Spinelli S, Alzari PM, Poljak RJ (1989) Nature 34: 877CrossRefGoogle Scholar
  5. Chothia C, Novotny L, Bruccoleri R, and Karplus M(1985) J Mol Bio 186: 651CrossRefGoogle Scholar
  6. Emery SC, and Adair JR (1994) Exp Opin Invest Drugs 3: 241CrossRefGoogle Scholar
  7. Foote J, and Winter G (1992) J Mol Biol 224: 487PubMedCrossRefGoogle Scholar
  8. Gavel Y, von Heinie G(1990) Protein Eng 3: 43CrossRefGoogle Scholar
  9. Gooley AA, Classon BJ, Marschalek R, William KL (1991) Biochem Biophys Res Cornmun 178: 1194CrossRefGoogle Scholar
  10. Jones PT, Dear PH, Foote J, Neuberger M S, Winter G (1986) Nature 321: 522PubMedCrossRefGoogle Scholar
  11. Kabat E A, Wu TT, Perry HM, Gottesman KS, Foeller C (1991) Sequences of proteins of immunological interest, Fifth Edition, U.S. Department of Health and Human Services, U.S. Government Printing OfficeGoogle Scholar
  12. Kettleborough CA, Saldanha J, Heath VJ, Morrison CJ, Bendig MM (1991) Protein Eng 4: 773PubMedCrossRefGoogle Scholar
  13. Kohler G, Milstein C 1975 Nature 256: 495PubMedCrossRefGoogle Scholar
  14. Kozak M (1987) J Mol Bio 196: 947CrossRefGoogle Scholar
  15. Maeda H, Matsushita S, Eda Y, Kimachi K, Tokiyoshi S, Bendig MM (1991) Hum Antibod Hvbridomas 2: 124Google Scholar
  16. Pisano A, Redmond JW, Williams KL, Gooley AA (1993) Glycobiology 3: 429PubMedCrossRefGoogle Scholar
  17. Riechmann L, Clark M, Waldmann H, Winter G (1988) Nature 332: 323PubMedCrossRefGoogle Scholar
  18. Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, Bendig MM (1993) Cancer Research 53: 851PubMedGoogle Scholar
  19. Stemmer WPC, (1995) Gene 146:49CrossRefGoogle Scholar
  20. Tramontano A, Chothia C, Lesk AM (1990) J Mol Biol 215:175PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  1. 1.AERES Biomedical LimitedMill Hill, LondonUK

Personalised recommendations